Bradmer appoints new board members
This article was originally published in Scrip
Executive Summary
Biopharmaceutical company Bradmer Pharmaceuticals, which specialises in the development and commercialisation of cancer therapies, has appointed Dr Donald Kufe and Charles Lilly to its board of directors.